Your browser doesn't support javascript.
Transmission potential of vaccinated and unvaccinated persons infected with the SARS-CoV-2 Delta variant in a federal prison, July-August 2021.
Salvatore, Phillip P; Lee, Christine C; Sleweon, Sadia; McCormick, David W; Nicolae, Lavinia; Knipe, Kristen; Dixon, Tom; Banta, Robert; Ogle, Isaac; Young, Cristen; Dusseau, Charles; Salmonson, Shawn; Ogden, Charles; Godwin, Eric; Ballom, TeCora; Rhodes, Tara; Wynn, Nhien Tran; David, Ebenezer; Bessey, Theresa K; Kim, Gimin; Suppiah, Suganthi; Tamin, Azaibi; Harcourt, Jennifer L; Sheth, Mili; Lowe, Luis; Browne, Hannah; Tate, Jacqueline E; Kirking, Hannah L; Hagan, Liesl M.
  • Salvatore PP; COVID-19 Pandemic Response Team, Centers for Disease Control and Prevention, Atlanta, GA, United States; United States Public Health Service, Rockville, MD, United States. Electronic address: pgx5@cdc.gov.
  • Lee CC; COVID-19 Pandemic Response Team, Centers for Disease Control and Prevention, Atlanta, GA, United States; Laboratory Leadership Service, Centers for Disease Control and Prevention, Atlanta, GA, United States.
  • Sleweon S; COVID-19 Pandemic Response Team, Centers for Disease Control and Prevention, Atlanta, GA, United States.
  • McCormick DW; COVID-19 Pandemic Response Team, Centers for Disease Control and Prevention, Atlanta, GA, United States; United States Public Health Service, Rockville, MD, United States; Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, GA, United States.
  • Nicolae L; COVID-19 Pandemic Response Team, Centers for Disease Control and Prevention, Atlanta, GA, United States.
  • Knipe K; COVID-19 Pandemic Response Team, Centers for Disease Control and Prevention, Atlanta, GA, United States.
  • Dixon T; Bureau of Prisons, U.S. Department of Justice, Washington, DC, United States.
  • Banta R; United States Public Health Service, Rockville, MD, United States; Bureau of Prisons, U.S. Department of Justice, Washington, DC, United States.
  • Ogle I; United States Public Health Service, Rockville, MD, United States; Bureau of Prisons, U.S. Department of Justice, Washington, DC, United States.
  • Young C; Bureau of Prisons, U.S. Department of Justice, Washington, DC, United States.
  • Dusseau C; United States Public Health Service, Rockville, MD, United States; Bureau of Prisons, U.S. Department of Justice, Washington, DC, United States.
  • Salmonson S; Bureau of Prisons, U.S. Department of Justice, Washington, DC, United States.
  • Ogden C; United States Public Health Service, Rockville, MD, United States; Bureau of Prisons, U.S. Department of Justice, Washington, DC, United States.
  • Godwin E; Bureau of Prisons, U.S. Department of Justice, Washington, DC, United States.
  • Ballom T; United States Public Health Service, Rockville, MD, United States; Bureau of Prisons, U.S. Department of Justice, Washington, DC, United States.
  • Rhodes T; United States Public Health Service, Rockville, MD, United States; Bureau of Prisons, U.S. Department of Justice, Washington, DC, United States.
  • Wynn NT; COVID-19 Pandemic Response Team, Centers for Disease Control and Prevention, Atlanta, GA, United States.
  • David E; COVID-19 Pandemic Response Team, Centers for Disease Control and Prevention, Atlanta, GA, United States.
  • Bessey TK; COVID-19 Pandemic Response Team, Centers for Disease Control and Prevention, Atlanta, GA, United States.
  • Kim G; COVID-19 Pandemic Response Team, Centers for Disease Control and Prevention, Atlanta, GA, United States.
  • Suppiah S; COVID-19 Pandemic Response Team, Centers for Disease Control and Prevention, Atlanta, GA, United States.
  • Tamin A; COVID-19 Pandemic Response Team, Centers for Disease Control and Prevention, Atlanta, GA, United States.
  • Harcourt JL; COVID-19 Pandemic Response Team, Centers for Disease Control and Prevention, Atlanta, GA, United States.
  • Sheth M; COVID-19 Pandemic Response Team, Centers for Disease Control and Prevention, Atlanta, GA, United States.
  • Lowe L; COVID-19 Pandemic Response Team, Centers for Disease Control and Prevention, Atlanta, GA, United States.
  • Browne H; COVID-19 Pandemic Response Team, Centers for Disease Control and Prevention, Atlanta, GA, United States.
  • Tate JE; COVID-19 Pandemic Response Team, Centers for Disease Control and Prevention, Atlanta, GA, United States; United States Public Health Service, Rockville, MD, United States.
  • Kirking HL; COVID-19 Pandemic Response Team, Centers for Disease Control and Prevention, Atlanta, GA, United States; United States Public Health Service, Rockville, MD, United States.
  • Hagan LM; COVID-19 Pandemic Response Team, Centers for Disease Control and Prevention, Atlanta, GA, United States.
Vaccine ; 41(11): 1808-1818, 2023 03 10.
Article in English | MEDLINE | ID: covidwho-2279516
ABSTRACT

BACKGROUND:

The extent to which vaccinated persons who become infected with SARS-CoV-2 contribute to transmission is unclear. During a SARS-CoV-2 Delta variant outbreak among incarcerated persons with high vaccination rates in a federal prison, we assessed markers of viral shedding in vaccinated and unvaccinated persons.

METHODS:

Consenting incarcerated persons with confirmed SARS-CoV-2 infection provided mid-turbinate nasal specimens daily for 10 consecutive days and reported symptom data via questionnaire. Real-time reverse transcription-polymerase chain reaction (RT-PCR), viral whole genome sequencing, and viral culture was performed on these nasal specimens. Duration of RT-PCR positivity and viral culture positivity was assessed using survival analysis.

RESULTS:

A total of 957 specimens were provided by 93 participants, of whom 78 (84 %) were vaccinated and 17 (16 %) were unvaccinated. No significant differences were detected in duration of RT-PCR positivity among vaccinated participants (median 13 days) versus those unvaccinated (median 13 days; p = 0.50), or in duration of culture positivity (medians 5 days and 5 days; p = 0.29). Among vaccinated participants, overall duration of culture positivity was shorter among Moderna vaccine recipients versus Pfizer (p = 0.048) or Janssen (p = 0.003) vaccine recipients. In post-hoc analyses, Moderna vaccine recipients demonstrated significantly shorter duration of culture positivity compared to unvaccinated participants (p = 0.02). When restricted to participants without reported prior infection, the difference between Moderna vaccine recipients and unvaccinated participants was more pronounced (medians 3 days and 6 days, p = 0.002).

CONCLUSIONS:

Infectious periods for vaccinated and unvaccinated persons who become infected with SARS-CoV-2 are similar and can be highly variable, though some vaccinated persons are likely infectious for shorter durations. These findings are critically important, especially in congregate settings where viral transmission can lead to large outbreaks. In such settings, clinicians and public health practitioners should consider vaccinated, infected persons to be no less infectious than unvaccinated, infected persons.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Prisons / COVID-19 Type of study: Observational study / Prognostic study Topics: Vaccines / Variants Limits: Humans Language: English Journal: Vaccine Year: 2023 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Prisons / COVID-19 Type of study: Observational study / Prognostic study Topics: Vaccines / Variants Limits: Humans Language: English Journal: Vaccine Year: 2023 Document Type: Article